Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 2

Almanac 2012: cardiovascular risk scores. The journals present selected research that has driven recent advances in clinical cardiology

Pages
195–201
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this context, they can be helpful in informing patients, motivating them to change their lifestyle, and reinforcing the importance of continued compliance.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Global risk scores use individual level information on non-modifiable risk factors (such as age, sex, ethnicity and family history) and modifi- able risk factors (such as smoking status and blood pressure) to predict an individual's absolute risk of an adverse event over a specified period of time in the future.
📊
Key Findings & Data:Cardiovascular risk scores have two major uses in practice.
💡
Conclusion & Impact:In this context, they can be helpful in informing patients, motivating them to change their lifestyle, and reinforcing the importance of continued compliance.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Global risk scores use individual level information on non-modifiable risk factors (such as age, sex, ethnicity and family history) and modifi- able risk factors (such as smoking status and blood pressure) to predict an individual's absolute risk of an adverse event over a specified period of time in the future. Cardiovascular risk scores have two major uses in practice. First, they can be used to dichotomise people into a group whose baseline risk, and therefore potential absolute benefit, is sufficiently high to justify the costs and risks associated with an intervention (whether treatment or prevention) and a group with a lower absolute risk to whom the intervention is usually denied. Second, they can be used to assess the effectiveness of an intervention (such as smoking cessation or antihypertensive treatment) at reducing an individual's risk of future adverse events. In this context, they can be helpful in informing patients, motivating them to change their lifestyle, and reinforcing the importance of continued compliance.

🔖

Cite This Article

PELL, J. P. (2022). Almanac 2012: cardiovascular risk scores. The journals present selected research that has driven recent advances in clinical cardiology. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 2, 195–201. https://ajindex.com/articles/436210

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Parkes G. Using risk scores with patients. BMJ 2010
  2. c3327. [CrossRef] 2. Cooper A, Nherera L, Calvert N, et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008. 3. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart 2011
  3. [CrossRef] 4. de la Iglesia B, Potter JF, Poulter NR, et al. Performance of the ASSIGN cardiovascular disease risk score on a UK cohort of patients from general practice. Heart 2011
  4. [CrossRef] 5. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010
  5. c3442. [CrossRef] 6. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefit or harms? A systematic review of the literature. BMC Health Serv Res 2008
  6. [CrossRef] 7. Liew SM, Doust J, Glasziou P Cardiovascular risk scores do not account for the effect of treatment: a review. Heart 2011
  7. [CrossRef] 8. Hippisley-Cox J, Coupland C, Robson R, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010
  8. c6624. [CrossRef] 9. Bueno H, Fernandez-Aviles F. Use of risk scores in acute coronary syndromes. Heart 2012
  9. [CrossRef] 10. Fox KA, Eagle KA, Gore JM, et al
  10. for the GRACE and GRACE2 Investigators. The Global Registry of acute coronary events, 1999 to 2009 - GRACE. Heart 2010
  11. [CrossRef] 11. O'Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION Predictive Risk Score Model. Circ Heart Fail 2012
  12. [CrossRef] 12. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospitality mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes 2010
  13. [CrossRef] 13. Van Dieren S, Beulens JW, Kengne AP et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012
  14. [CrossRef] 14. Meland